Publications by authors named "David Jackman"

Claim this Profile
U
Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer.
Cody E Cotner, Angela C Tramontano, Alex Post, Brian Finn, Saima Awan, David M Jackman

JCO Oncol Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Defactinib (VS6063) in Patients With Tumors With Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, James A Zwiebel, Robert J Gray

JCO Precis Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Findings on the Use of Clinical Pathways for Management of Unwarranted Variation in Cancer Care.
David M Jackman, Emily Foster, Joanna M Hamilton, Carole Tremonti, Craig A Bunnell

Am J Med Qual· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons from the front: designing and implementing clinical pathways by and for clinicians.
David M Jackman, Joanna Hamilton, Emily Foster, Craig A Bunnell, Louis Culot

Am J Manag Care· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Lecia V Sequist, Jhanelle Elaine Gray, Wael A Harb, Ariel Lopez-Chavez, Robert C Doebele, David Michael Jackman

Oncologist· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record.
Sarah S Kadish, Erica L Mayer, David M Jackman, Mark Pomerantz, Lauren Brady

J Oncol Pract· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
Scott Gettinger, Leora Horn, David Jackman, David Spigel, Scott Antonia

J Clin Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Douglas E Wood, Ella A Kazerooni, Scott L Baum, George A Eapen, David S Ettinger, David M Jackman

J Natl Compr Canc Netw· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.
David M Jackman, Yichen Zhang, Carole Dalby, Tom Nguyen, Julia Nagle

J Oncol Pract· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Masahiko Yanagita, Amanda J Redig, Cloud P Paweletz, Suzanne E Dahlberg, Allison O'Connell, David M Jackman

Clin Cancer Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.
Vishesh Agrawal, Thibaud P Coroller, Ying Hou, Stephanie W Lee, John L Romano, David M Jackman

Lung Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.
Amanda J Redig, Daniel B Costa, Myriam Taibi, David Boucher, Bruce E Johnson, David M Jackman

JAMA Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer.
Richard Li, Gretchen Hermann, Elizabeth Baldini, Aileen Chen, David Jackman

Lung Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
Jessica J Lin, Stephanie Cardarella, Christine A Lydon, Suzanne E Dahlberg, David M Jackman

J Thorac Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall

J Clin Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Antonio Calles, Xiaoyun Liao, Lynette M Sholl, Scott J Rodig, Gordon J Freeman, David M Jackman

J Thorac Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Anna F Farago, Long P Le, Zongli Zheng, Alona Muzikansky, Alexander Drilon, David Jackman

J Thorac Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Peter C Lo, Suzanne E Dahlberg, Mizuki Nishino, Bruce E Johnson, Lecia V Sequist, David M Jackman

Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Antonio Calles, Lynette M Sholl, Scott J Rodig, Ashley K Pelton, Jason L Hornick, David M Jackman

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Scott N Gettinger, Leora Horn, Leena Gandhi, David R Spigel, Scott J Antonia, David M Jackman

J Clin Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.
Mizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, Tetsuro Araki, Christine Lydon, David M Jackman

Eur J Radiol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
David M Jackman, Leigh A Cioffredi, Lorraine Jacobs, Farhana Sharmeen, Linda K Morse

Oncotarget· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.
Douglas E Wood, Ella Kazerooni, Scott L Baum, Mark T Dransfield, George A Eapen, David M Jackman

J Natl Compr Canc Netw· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.
Phillip J Gray, Raymond H Mak, Beow Y Yeap, Sarah K Cryer, Nancy E Pinnell, David M Jackman

Lung Cancer· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.
Ravi B Parikh, Angel M Cronin, David E Kozono, Geoffrey R Oxnard, Raymond H Mak, David M Jackman

Int J Radiat Oncol Biol Phys· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis